Aromatase inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk m (→References) |
imported>Meg Taylor No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s. Because of this action, these inhibitors are sometimes used to treat cancerous tumors which are estrogen-sensitive. At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> : | '''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially [[breast cancer]] in postmenopausal women. At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> : | ||
* [[anastrazole]] (Arimidex®) | * [[anastrazole]] (Arimidex®) | ||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{reflist}} | |||
Revision as of 03:15, 7 October 2013
Aromatase inhibitors, which inhibit the enzyme aromatase used biologically to produce estrogens, inhibit the biosynthetic production of estrogen steroids. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially breast cancer in postmenopausal women. At present, three AIs are approved by the FDA[1] :
- anastrazole (Arimidex®)
- exemestane (Aromasin®)
- letrozole (Femara®)